Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc. was founded as a corporate entity but has not publicly disclosed its founding year or founding principals. The company's primary asset is the ChemoPure platform, a blood purification system intended to reduce side effects of chemotherapy by removing residual drugs from circulation post-treatment. As of public records, the firm has not reported revenue or commercial operations, and its status as an investment vehicle is unconfirmed. The company does not appear to manage capital or deploy assets in sectors, stages, or geographies typical of family offices or asset managers. No named portfolio companies, deals, or co-investors have been disclosed. The geographic footprint is unknown, and no team size or professional headcount has been published. No recent operational events within the last 24 months have been identified. The firm has not announced fundraising, partnerships, or clinical milestones since its public availability. Adjacent vehicles such as foundations or operating companies are not disclosed. Structural differentiator: Sigyn Therapeutics represents a single-asset therapeutic developer with no disclosed investment mandate or capital management activity. This distinguishes it from conventional family offices or allocators, which typically operate diversified portfolios.